Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Rogaratinib Vs. Chemotherapy in Advanced or Metastatic UC Patients Based on FGFR1/3 mRNA Expression

admin by admin
March 13, 2023
in News


The following is a summary of “FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression,” published in the January 2023 issue of Oncology by Sternberg, et al.


In patients with advanced urothelial carcinoma (UC) with FGFR1-3 mRNA overexpression, rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, has shown encouraging phase I effectiveness and safety. For a study, researchers compared the effectiveness and safety of rogaratinib versus chemotherapy in patients with advanced/metastatic UC who had previously received platinum chemotherapy and tested positive for FGFR mRNA.

Phase II/III, randomized, open-label experiment FORT-1. Rogaratinib (800 mg orally twice daily, 3-week cycles; n = 87) or chemotherapy (docetaxel 75 mg/m2, paclitaxel 175 mg/m2, or vinflunine 320 mg/m2 intravenously once every 3 weeks; n = 88) were randomly assigned (1:1) to patients with FGFR1/3 mRNA-positive locally advanced or metastatic UC with ≥1 prior platinum-containing regimen. Overall survival was the main outcome, and an objective response rate (ORR) analysis was scheduled for after phase II enrollment. Enrollment was halted before phase III of the study was advanced due to the equivalent efficacy of the medications; a thorough interim analysis of phase II was done.

ORRs were 20.7% for rogaratinib (18/87; 95% CI: 12.7 to 30.7) and 19.3% for chemotherapy (17/88; 11.7 to 29.1). Overall median survival ranged between 8.3 and 9.8 months (95% CI, 6.5 to not estimable; hazard ratio, 1.11; 95% CI, 0.71 to 1.72; P =.67). Both 32 (39.0%)/15 (18.3%) and 37 (43.0%)/4 (4.7%) individuals experienced grade 3/4 incidents. There were no deaths brought on by rogaratinib. ORRs for rogaratinib were 52.4% (11/21; 95% CI, 29.8 to 74.3), and for chemotherapy 26.7% (4/15; 95% CI, 7.8 to 55.1). These results were from the exploratory investigation of patients with FGFR3 DNA mutations.

These were the first findings that showed comparable efficacy and tolerable safety when FGFR-directed treatment and chemotherapy are used in individuals with FGFR-altered UC. A preliminary analysis revealed that FGFR3 DNA changes in combination with FGFR1/3 mRNA overexpression may be more accurate indicators of rogaratinib response.

Reference: ascopubs.org/doi/full/10.1200/JCO.21.02303



Source link

Advertisement Banner
Previous Post

Managing An Actively Bleeding Airway

Next Post

A big data COVID train wreck – The Health Care Blog

Related Posts

News

#VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

March 26, 2023
News

Over-the-Scope Clip Beneficial for Nonvariceal Upper GI Bleeding

March 25, 2023
News

Patients with Burns and a Multimodal Pain Management Approach

March 24, 2023
News

Insights from Normalization Process Theory

March 23, 2023
News

Transdermal Testosterone Pretreatment Improves Live Birth Rates in Poor Responders

March 22, 2023
News

Ph-positive Acute Lymphoblastic Leukaemia Treated with Ponatinib and Blinatumomab

March 21, 2023
Next Post

A big data COVID train wreck – The Health Care Blog

Recommended

Promises Made – Promises Kept:  President Biden’s Support for “Obamacare.” – The Health Care Blog

5 months ago

Microsoft’s Nuance adds ChatGPT successor GPT-4 to EHR

6 days ago

More meaningful coverage of firearm violence requires ‘radical empathy’

5 months ago

Give Kids a Healthy Itch – The Health Care Blog

4 months ago

CMS nursing home ownership rule targets private equity

1 month ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.